StimCardio Raises $30M Series A for Wearable AF Therapeutic

StimCardio announced $30M in Series A financing on October 29, 2026. StimCardio announced the closing of an oversubscribed $30 million Series A led by Metis Medtech, expected to fund the company through its planned NeuroPulse 2 pivotal study and preparation for an FDA De Novo submission.

Round details

The financing includes backing from Metis Medtech, Catalyst Health Ventures. The company did not publish a valuation with the announcement.

Round: Series A
Capital announced: $30M

How the company plans to use the capital

The financing is expected to fund StimCardio through its planned NeuroPulse 2 pivotal study and support preparation of a De Novo submission to the U.S. Food and Drug Administration.

Why this matters for GTM teams

The company describes the round as oversubscribed, with participation from Catalyst Health Ventures, multiple corporate strategic investors and other new and existing investors, and says the financing follows peer-reviewed NeuroPulse pilot study results.

Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.

Source and methodology

This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.

Primary source: StimCardio Series A announcement.